Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction

Circulation

Volumn 106, Issue 24, 2002, Pages 3126-3132

  Shiomi, Tetsuya ^a   Tsutsui, Hiroyuki ^a   Hayashidani, Shunji ^a   Suematsu, Nobuhiro ^a   Ikeuchi, Masaki ^a   Wen, Jing ^a   Ishibashi, Minako ^a   Kubota, Toru ^a   Egashira, Kensuke ^a   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Heart failure; Myocardial infarction; Myocardium; Receptors; Remodeling

Indexed keywords

CHEMOKINE; CYTOKINE; GELATINASE B; GLUCOSE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFECT; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE FIBROSIS; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD GLUCOSE; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEMODYNAMIC PROCESSES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OBSERVER VARIATION; ORGAN SIZE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SURVIVAL RATE; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 0037058874     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000039346.31538.2C     Document Type: Article

References (26)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.
2. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327: 669-677.
3. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature. 2000;405:421-424.
4. Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000;10:238-245.
5. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
6. Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res. 2000;87: 596-602.
7. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation. 1999;99:1492-1498.
8. Sam F, Sawyer DB, Xie Z, et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res. 2001;89: 351-356.
9. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
10. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;105:868-873.
11. Yamashita K, Murakami H, Okuda T, et al. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J Chromatogr B Biomed Appl. 1996;677: 141-116.
12. Litwin SE, Katz SE, Morgan JP, et al. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994;89:345-354.
13. Patten RD, Aronovitz MJ, Deras-Mejia L, et al. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol. 1998;274: H1812-H1820.
14. Hoit BD, Khoury SF, Kranias EG, et al. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77:632-637.
15. Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation. 2000;101:2518-2525.
16. Yue TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation. 2001;104:2588-2594.
17. Yamamoto K, Ohki R, Lee RT, et al. Peroxisome proliferator-activated receptor γ activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104:1670-1675.
18. Lee H, Shi W, Tontonoz P, et al. Role for peroxisome proliferator-activated receptor α in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000;87:516-521.
19. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389.
20. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164:6503-6508.
21. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
22. Shioi T, Matsumori A, Kihara Y, et al. Increased expression of interleukin-1β and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res. 1997;81:664-671.
23. Marx N, Schonbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res. 1998;83:1097-1103.
24. Kaplan F, Al-Majali K, Betteridge DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk. 2001;8:211-217.
25. Hart CY, Burnett JC Jr, Redfield MM. Effects of Avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol. 2001;281:H1938-H1945.
26. Kass DA, Hare JM, Georgakopoulos D. Murine cardiac function: A cautionary tail. Circ Res. 1998;82:519-522.